CNX Therapeutics’ €56.5m Acquisition of Eisai’s Rights in Loxapac and Parkinane

Georgio Naffaa
Tagged:

Simmons & Simmons advised Eisai on the divestment.Eisai S.A.S, the French subsidiary of Eisai Co., Ltd., has transferred its rights to Loxapac (loxapine) and Parkinane LP…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Georgio Naffaa

…

This content is for Standard 1 Year members only.
Login Join Now